Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.

In this report, we examine the preclinical development of glasdegib, its pharmacology and the clinical investigation that demonstrated its safety and efficacy, resulting in its approval. Additionally, we highlight ongoing investigation and future applications of this therapy. PMID: 31584572 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31584572?dopt=Abstract

Source: Drugs of Today - October 5, 2019 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research